Boehringer

Boehringer Ingelheim Makes Rapid Shift to Digital Engagement with Veeva CRM Engage Meeting

Retrieved on: 
Wednesday, March 24, 2021
Technology, Marketing, Communications, Software, Practice Management, Biotechnology, Internet, Pharmaceutical, Health, Data management, Veeva Systems, Boehringer, Companies, Computer companies, Industry economics)

Boehringer Ingelheim , a top 20 global pharmaceutical company, is standardizing on Veeva CRM Engage Meeting to drive more valued interactions between its global field organization and healthcare providers (HCPs).

Key Points: 
  • Boehringer Ingelheim , a top 20 global pharmaceutical company, is standardizing on Veeva CRM Engage Meeting to drive more valued interactions between its global field organization and healthcare providers (HCPs).
  • The companys adoption of Veeva CRM Engage Meeting builds upon its success using Veeva CRM for multichannel engagement, including Veeva CRM Approved Email , Veeva Events , and Veeva Align .
  • Boehringer Ingelheim also uses Veeva Vault PromoMats and Veeva Vault MedComms to more quickly create compliant digital content that field teams use during engagements with HCPs.
  • For more on Veeva CRM Engage Meeting, visit: veeva.com/EngageMeeting
    Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
    Veeva is the global leader in cloud software for the life sciences industry.

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Retrieved on: 
Wednesday, March 24, 2021
Biotechnology, Health, Veterinary, Pharmaceutical, Clinical trials, Boehringer Ingelheim, Boehringer, Ingelheim am Rhein, WE, Economy of Germany, Germany, Companies

2020 was a good year for Boehringer Ingelheim, although the effects of the COVID-19 pandemic were omnipresent.

Key Points: 
  • 2020 was a good year for Boehringer Ingelheim, although the effects of the COVID-19 pandemic were omnipresent.
  • The United States remains the largest market for Boehringer Ingelheim with the highest regional net sales in the Human Pharma business.
  • 60% of the top 20 pharmaceutical companies and innovative biotech firms are clients of Boehringer Ingelheims Biopharmaceutical Contract Manufacturing business, known under the brand name Boehringer Ingelheim BioXcellenceTM.
  • For 2021, Boehringer Ingelheim expects to achieve a slight year-on-year increase in net sales on a comparable basis.

Saniona publishes its year-end report for 2020

Retrieved on: 
Wednesday, March 17, 2021
Companies, Pharmaceutical companies, Boehringer Ingelheim, Industry economics), Boehringer, Prader, Novartis

Saniona received written feedback fromthe U.S. Food and Drug Administration (FDA) regarding pre-Investigational New Drug (IND) submissions for Tesomet in Prader-Willi syndrome (PWS) and HO.

Key Points: 
  • Saniona received written feedback fromthe U.S. Food and Drug Administration (FDA) regarding pre-Investigational New Drug (IND) submissions for Tesomet in Prader-Willi syndrome (PWS) and HO.
  • Saniona refined its pipeline, regaining exclusive, global rights to its GABAa5 negative allosteric modulator program from Boehringer Ingelheim, which terminated this collaboration for strategic reasons.This does not impact the 2020 collaboration between Saniona and Boehringer Ingelheim, which remains ongoing.
  • Saniona received an upfront payment of approximately USD 2.9 million (SEK 24.2 million) relating to Novartiss acquisition of Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%.
  • Based on this feedback, Saniona is proceeding with plans to initiate a Phase 2b study in HO in the first half of this year.

Anitox Names New Global Director of Nutrition and Live Production

Retrieved on: 
Monday, March 8, 2021
Boehringer Ingelheim, Boehringer Ingelheim Animal Health, Sanofi, Pharmaceutical companies, Boehringer, Veterinarian, Montiel, Ingelheim am Rhein, States of Germany, Economy of Germany

LAWRENCEVILLE, Ga., March 8, 2021 /PRNewswire/ -- Anitox, the global leader in pathogen control and milling efficiency programs for the primary meat, egg and fish production sectors, announced that Dr. Enrique Montiel joined the company as Director of Nutrition and Live Production on Monday, March 1.

Key Points: 
  • LAWRENCEVILLE, Ga., March 8, 2021 /PRNewswire/ -- Anitox, the global leader in pathogen control and milling efficiency programs for the primary meat, egg and fish production sectors, announced that Dr. Enrique Montiel joined the company as Director of Nutrition and Live Production on Monday, March 1.
  • Most recently he served as Director of Global Avian Veterinary Services for Merial, then as Senior Veterinarian for Boehringer Ingelheim Animal Health.
  • Dr. Montiel added, "I am excited to join the Anitox team at a such a critical time for our industry.
  • Global pathogen control specialist Anitox is a privately owned and operated company with more than 100 employees worldwide.

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Retrieved on: 
Tuesday, March 2, 2021
Organic compounds, Clinical medicine, Medicine, Oncology, G1 Therapeutics, Protein kinase inhibitors, Trilaciclib, Boehringer Ingelheim, Bone marrow suppression, Chemotherapy, Boehringer, Cancer

It is the first and only therapy designed to help protect bone marrow (myeloprotection) when administered prior to treatment with chemotherapy.

Key Points: 
  • It is the first and only therapy designed to help protect bone marrow (myeloprotection) when administered prior to treatment with chemotherapy.
  • COSELA(trilaciclib) is the first and only myeloprotection therapy to help decrease the incidence of chemotherapy-induced myelosuppression.
  • G1 Therapeutics and the G1 Therapeutics logo, COSELA and the COSELA logo, G1 to One and the G1 to One logo are trademarks of G1 Therapeutics, Inc.
    Cancer takes.
  • In addition, there are Boehringer Ingelheim Animal Health in Duluth, GA and Boehringer Ingelheim Fremont, Inc. in Fremont, CA.

Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity

Retrieved on: 
Monday, March 1, 2021
Health, Fitness & Nutrition, Clinical trials, Research, Pharmaceutical, Science, Boehringer Ingelheim, Boehringer, Ingelheim am Rhein, Economy of Germany, Germany, Companies

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity.

Key Points: 
  • Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity.
  • The companies share the goal of providing new obesity therapies with increased tolerability that support greater weight loss than current therapy options.
  • This marks the third joint research program between Boehringer Ingelheim and Gubra in the area of obesity since 2017, said Sren Tullin, Ph.D., Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim.
  • We are particularly pleased about this third collaboration with Boehringer Ingelheim, said Henrik Blou, CEO of Gubra.

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

Retrieved on: 
Tuesday, February 16, 2021
Boehringer Ingelheim, Pharmaceutical companies, Ingelheim am Rhein, Companies, Boehringer, States of Germany, WE

DULUTH, Ga., Feb. 16, 2021 /PRNewswire/ --Boehringer Ingelheim Animal Health USA Inc. today announced the creation of Pawru, Inc. as a separate Company within the Boehringer Ingelheim Animal Health business.

Key Points: 
  • DULUTH, Ga., Feb. 16, 2021 /PRNewswire/ --Boehringer Ingelheim Animal Health USA Inc. today announced the creation of Pawru, Inc. as a separate Company within the Boehringer Ingelheim Animal Health business.
  • "Since expanding PetPro Connect to the entire United States less than a year ago, we have gained incredible insight into the opportunities for advancing pet health and wellness using innovative digital technologies," said Heath Wilkes, Head of U.S. Digital Health at Boehringer Ingelheim Animal Health.
  • Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.5 billion (4 billion euros) in 2019 and a presence in more than 150 countries.
  • Boehringer Ingelheim Animal Health has a significant presence in the United States,with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico.

Adimab Provides Year-End Update on 2020 Partnership Activities

Retrieved on: 
Thursday, February 11, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Companies, Boehringer Ingelheim, Bristol Myers Squibb, Boehringer, Ingelheim am Rhein, Life sciences

In addition, Adimab announced the expansion of seven of its current partnerships and the achievement of 50 technical and development milestones across numerous collaborations.

Key Points: 
  • In addition, Adimab announced the expansion of seven of its current partnerships and the achievement of 50 technical and development milestones across numerous collaborations.
  • In 2020, Adimab and its partners initiated 45 new therapeutic programs.
  • In addition, Adimab expanded its collaborations with Acceleron, Bristol Myers Squibb, Boehringer Ingelheim, IASO, TRex Bio and others.
  • At the end of that assessment, we want them to raise their hand and ask to continue to use Adimab for their therapeutic programs.

Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition

Retrieved on: 
Wednesday, January 13, 2021
Boehringer Ingelheim, Boehringer Ingelheim Animal Health, Sanofi, Pharmaceutical companies, Companies, Ingelheim am Rhein, Economy of Germany, Boehringer, Elanco

He is based at the U.S. headquarters of Boehringer Ingelheim Animal Health in Duluth, Ga.

Key Points: 
  • He is based at the U.S. headquarters of Boehringer Ingelheim Animal Health in Duluth, Ga.
    Hoekstra retired after holding a variety of leadership roles at Boehringer Ingelheim.
  • As president of Boehringer Ingelheim Animal Health in the U.S. for the last two years, he oversaw the final integration activities after Boehringer Ingelheim acquired Merial in 2017 to become the world's second-largest animal health company.
  • Boehringer Ingelheim Animal Health also is transitioning a key global manufacturing role from its global headquarters in Ingelheim, Germany, to the United States.
  • Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.5 billion (4 billion euros) in 2019 andapresence in more than 150 countries.

Boehringer Ingelheim receives EMA marketing authorization for NexGard® COMBO, the first isoxazoline-based full endectocide for cats

Retrieved on: 
Wednesday, January 13, 2021
Health, Consumer, Infectious diseases, Pets, Pharmaceutical, Veterinary, Chemical compounds, Insecticides, Organic compounds, Boehringer Ingelheim, Acaricides, Afoxolaner, Chloroarenes, Isoxazoles, Boehringer Ingelheim Animal Health, Pharmaceutical companies, Boehringer, Cat

Boehringer Ingelheim, a global leader in animal health, is proud to announce that it has received marketing authorization from the EMA (European Medicine Agency) and European Commission for its NexGard COMBO topical solution for cats.

Key Points: 
  • Boehringer Ingelheim, a global leader in animal health, is proud to announce that it has received marketing authorization from the EMA (European Medicine Agency) and European Commission for its NexGard COMBO topical solution for cats.
  • NexGard COMBO offers unparalleled protection for cats: It kills a broader range of parasites than any other isoxazoline-based cat parasiticide currently available on the market.
  • NexGard COMBO is the first isoxazoline-based full endectocide developed specifically for cats, shares Dr. Craig Beck, Global Franchise Head NexGard, Boehringer Ingelheim Animal Health.
  • Were dedicated to being the global leader in feline health care and the launch of NexGard COMBO for cats expands our trusted feline product portfolio.